Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 31 March 2024.
Operational highlights (including post-period end)
· The Board continues to be encouraged by the positive data generated to date on NXP002 in context to the evolving treatment landscape and understanding of future patient needs in the treatment of fibrosing interstitial lung diseases. Preliminary discussions have been initiated with potential partners and are on-going.
· Notice of Allowance was received for the Japanese National Phase Patent Application No. 2020-555115 for NXP002 entitled “CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE” which has now formally granted. Notice of Allowance has also been received from the European Patent Office for the European National Phase Application, with formal granting complete. This patent describes proprietary new forms of tranilast being progressed by the Company as NXP002 as a potential novel idiopathic pulmonary fibrosis (“IPF”) treatment. These proprietary drug forms uniquely enable drug delivery via an inhaled nebulised formulation.
